Premium
Altered platelet reactivity in humans diagnosed with type 2 diabetes mellitus
Author(s) -
Vesci Joanne,
Apopa Patrick L,
Yeung Jennifer,
Holinstat Michael
Publication year - 2011
Publication title -
the faseb journal
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.709
H-Index - 277
eISSN - 1530-6860
pISSN - 0892-6638
DOI - 10.1096/fasebj.25.1_supplement.1089.5
Subject(s) - platelet , medicine , endocrinology , diabetes mellitus , platelet activation , type 2 diabetes , type 2 diabetes mellitus
Cardiovascular disease is the leading cause of death in the United States and although platelets are thought to play a crucial role in the progression of type 2 diabetes mellitus (type 2 DM), the underlying mechanism(s) regulating platelet function in diabetes is unclear. To gain an understanding of how Type 2 DM may alter platelet reactivity, platelet function was phenotyped in African American and Caucasian subjects diagnosed with or without Type 2 DM. Platelets were stimulated with low and high concentrations of thrombin, PAR1‐AP, PAR4‐AP, or ADP and platelet aggregation, granule secretion, integrin activation and Rap1 activation were measured. The data was analyzed for differences based on race, gender, and BMI, both within the type 2 DM group as well as between type 2 DM and control subjects. In the control versus diabetes comparison, significant differences were observed in aggregation, dense granule secretion, integrin activation, and Rap1 activation, whereas calcium mobilization was not affected. Within the diabetic group, significant differences were observed in gender as well as race. These data support a central role for platelet reactivity in type 2 DM. Understanding these differences may lead to better targeting of anti‐platelet therapies in the treatment of type 2 DM. This work was supported by NIH grants HL081009 and HL089457.